Charles River Laboratories International (CRL) Common Equity: 2009-2024
Historic Common Equity for Charles River Laboratories International (CRL) over the last 16 years, with Dec 2024 value amounting to $3.5 billion.
- Charles River Laboratories International's Common Equity fell 9.95% to $3.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year decrease of 9.95%. This contributed to the annual value of $3.5 billion for FY2024, which is 3.76% down from last year.
- Latest data reveals that Charles River Laboratories International reported Common Equity of $3.5 billion as of FY2024, which was down 3.76% from $3.6 billion recorded in FY2023.
- Charles River Laboratories International's 5-year Common Equity high stood at $3.6 billion for FY2023, and its period low was $2.1 billion during FY2020.
- For the 3-year period, Charles River Laboratories International's Common Equity averaged around $3.4 billion, with its median value being $3.5 billion (2024).
- As far as peak fluctuations go, Charles River Laboratories International's Common Equity rose by 29.33% in 2020, and later dropped by 3.76% in 2024.
- Yearly analysis of 5 years shows Charles River Laboratories International's Common Equity stood at $2.1 billion in 2020, then climbed by 19.87% to $2.5 billion in 2021, then climbed by 17.41% to $3.0 billion in 2022, then grew by 20.84% to $3.6 billion in 2023, then decreased by 3.76% to $3.5 billion in 2024.